ArticleBMC microbiology2026
Bio-functional Levilactobacillus brevis strains of feline origin: the potential probiotic food adjunct for companion animals.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Although autochthonous probiotic application is considered standard for the host-specific environment, the allochthonous probiotics also deliver valuable physiological or therapeutic benefits during their transit period before being eliminated naturally. This study evaluated the probiotic and bio-functional attributes of seven zoo feline-derived Levilactobacillus brevis strains for their potential application in companion animals or functional food industry. In vitro methods were employed to assess their survival under simulated gastrointestinal tract (GIT) conditions, safety profiles (hemolytic activity, DNase activity, and antibiotic susceptibility), and bio-functional potential (antimicrobial, antioxidant, and hypocholesterolemic activities). All strains exhibited high survival in the presence of lysozyme (69.0-96.7%), gastric juice (60.7-91.3%), and bile concentrations (up to 78.4-92.2% at 1.8% bile). The isolates displayed strong hydrophobicity (41.7-85.5%) and auto-aggregation properties (29.8-75.2%), and no signs of toxicity (non-hemolytic and DNase negative). Significant variations were noticed among strains with reference to their probiotic and bio-functional properties (p < 0.05). Furthermore, the strains secreted antioxidant metabolites capable of scavenging 2, 2-diphenyl-1-picrylhydrazyl (62-72%), hydroxyl (54-65%), and superoxide (57-69%) radicals. Among selected isolates, strain Lb I (L. brevis MZ400640) demonstrated the strongest antagonistic activity against both Gram-positive and Gram-negative pathogens. The bile salt hydrolase (BSH) gene was conserved across all seven isolates, confirming their ability to deconjugate major mammalian bile salts, sodium glycoholate and taurocholate. Out of the 14 parameters evaluated, strain Lb VII (L. brevis MW450245) exhibited most robust overall performance highlighting the potential of Lb VII as a functional probiotic feed additive to promote health and manage hypercholesterolemia in companion animals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.